What is MaxCyte's cash ratio?

MaxCyte (MXCT) reported cash ratio of 1.4× in Q1 2026.

How has MaxCyte's cash ratio changed year-over-year?

MaxCyte's cash ratio decreased by 22.4% year-over-year, from 1.8× to 1.4×.

What is the long-term trend for MaxCyte's cash ratio?

Over 5 years (2020 to 2025), MaxCyte's cash ratio has grown at a -2.7% compound annual growth rate (CAGR), from 1.6× to 1.4×.

What does cash ratio mean?

Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.

MaxCyte MXCT Cash ratio

Cash ratio at other companies

Bio-Rad LaboratoriesBIO

0.6×-0.5×

Thermo Fisher ScientificTMO

0.2×-0.1×

Ginkgo BioworksDNA

2.4×-0.7×

Immix Biopharma, Inc.IMMX

7.5×+5.8×

Rapid Micro BiosystemsRPID

0.7×-0.5×

PDE

Pro-Dex, Inc.PDEX

0.7×+0.4×

Other financials

Income statement

See full

Revenue$9.7M-7.1%

Gross profit$8.1M-9.1%

Operating income-$6.2M+49.7%

Net income-$4.8M+53.7%

EPS (diluted)-$0.04+60.0%

Balance sheet

See full

Cash & equivalents$14.6M-37.8%

Total debt$17.5M-7.1%

Total equity$167.9M-15.8%

Total assets$194.5M-15.4%

Cash flow

See full

Operating cash flow-$8.2M+43.3%

CapEx$72.0K-89.0%

Free cash flow-$8.2M+45.3%

Valuation

See full

Market cap$130.15M-46.8%

Enterprise value$133.08M-46.3%

P/S4×-2.8×

Profitability

See full

Gross margin80.5%-0.4pp

Operating margin-141.8%+6.4pp

Net margin-121.2%+12.3pp

FCF margin-90.9%+3.7pp

Returns & leverage

See full

Return on equity-21.3%+2.0pp

Debt / equity0.1×0.0×

Current ratio12×-0.2×

Where this comes from

Calculated from MaxCyte’s reported figures.

cash and equivalents/total current liabilities=1.4×

Based on the most recent quarter.

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MaxCyte's cash ratio?: MaxCyte (MXCT) reported cash ratio of 1.4× in Q1 2026.
How has MaxCyte's cash ratio changed year-over-year?: MaxCyte's cash ratio decreased by 22.4% year-over-year, from 1.8× to 1.4×.
What is the long-term trend for MaxCyte's cash ratio?: Over 5 years (2020 to 2025), MaxCyte's cash ratio has grown at a -2.7% compound annual growth rate (CAGR), from 1.6× to 1.4×.
What does cash ratio mean?: Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.